Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a Healthcare company (Biotechnology) with a market capitalization of $230M. The Maz Rating grades it against the other companies in its sector.
Arcturus Therapeutics Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.97, Arcturus Therapeutics Holdings Inc. trades at 9.1x sales and 1.3x book value. Over the last twelve months it generated about $25M of revenue and a net loss of $90M. It runs a gross margin of 97.4%, an operating margin of -384.1% and a net margin of -349.7%. It shows return on equity of -46.8%, return on invested capital of -50.3% and a free cash flow yield of -27.4%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 6.68. Over the past 52 weeks the share price ranged from $5.50 to $17.96, with a beta of 2.60.
Arcturus Therapeutics Holdings Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 12 Buy, 5 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Arcturus Therapeutics Holdings Inc. (ARCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 51.8% / 30% · Interest income / Revenue 9.69% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 51.8% / 33% · Receivables / Mkt Cap (36m) 0.35% / 49% · Interest income / Revenue 9.69% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 51.8% / 33.33% · Receivables / Mkt Cap (24m) 0.35% / 33.33% · Interest income / Revenue 9.69% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.06% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 85.6% / 33.33% · Receivables / Avg Assets (4Q) 1.04% / 33.33% · Interest income / Revenue 9.69% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 85.8% / 33.33% · (Cash+Recv) / Total Assets 86.4% / 33.33% · Interest income / Revenue 9.69% / 5% | Fail |
No. As of September 2026, Arcturus Therapeutics Holdings Inc. (ARCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Arcturus Therapeutics Holdings Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 9.69% of each dividend: Arcturus Therapeutics Holdings Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.